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Abstract: This study aimed to evaluate the anti-cancer effect of a combination therapy of miRNA-29b
and genistein loaded in mucin-1 (MUC 1)-aptamer functionalized hybrid nanoparticles in non-small
cell lung cancer (NSCLC) A549 cell line. Genistein-miRNA-29b-loaded hybrid nanoparticles (GMLHN)
was prepared and characterized. Particle size and zeta potential were measured using photon
correlation spectroscopy (PCS). Encapsulation efficiency and loading efficiency were determined
using HPLC. Preferential internalization of MUC 1-aptamer functionalized GMLHN by A549 cells
was evaluated and compared to normal MRC-5 cells. The ability of GMLHN to downregulate targeted
oncoproteins Phosphorylated protein kinase, strain AK, Thymoma (Phosphorylated protein kinase B)
(pAKT), Phosphorylated phosphoinositide 3-kinase (p-PI3K), DNA (cytosine-5-)-methyltransferase
3 beta (DNMT3B) and Myeloid Cell Leukemia Sequence 1 (MCL 1) was evaluated using western
blot, while antiproliferative effect and ability to initiate apoptosis was also assessed in A549 cells.
MUC 1-aptamer functionalized GMLHN nanoparticles were prepared. These nanoparticles were
preferentially internalized by A549 cells but less so, in MRC-5 cells. pAKT, p-PI3K, DNMT3B and
MCL 1 were efficiently downregulated by these nanoparticles without affecting the levels of AKT and
PI3K in A549 cells. GMLHN demonstrated a superior antiproliferative effect compared to individual
genistein and miRNA-29b-loaded nanoparticles. Results generated were able to demonstrate that
genistein-miRNA-29b-loaded hybrid nanoparticles (GMLHN) could be a potential treatment modality
for NSCLC because of the ability of the payloads to attack multiple targets.
Keywords: hybrid nanoparticles; genistein; microRNA-29b; combination therapy; mucin-1 MUC1;
aptamer; non-small cell lung cancer
1. Introduction
The leading cause of cancer death is non-small cell lung cancer (NSCLC). In the United states,
only a five-year survival rate of 15% has been achieved for all stages of NSCLC [1,2]. Recent
breakthroughs in the development of chemotherapy has not reflected significantly in cure rates, which
still stands at less than 18% [3]. Due to the fact that cytoreductive surgery has not been very effective
because of the quick spread of NSCLC, chemotherapy in combination with radiotherapy has been the
treatments of choice. However, resistance of cancer cells to chemotherapy has led to limited efficacy of
conventional chemotherapy [3–5]. The investment of several billions of dollars in research on cancer
drug development has not had any substantial decrease in mortality for several decades [6]. Hence,
there is a need to try different modalities, to help improve the outcome of chemotherapy in NSCLC.
Our present study aims to co-encapsulate miRNA-29b with genistein in hybrid nanoparticles
(GMLHN) to produce a combination therapy that will effectively treat NSCLC. Genistein is naturally
found in soy products and is known to elevate the antitumor effect of some chemotherapeutic
agents in several tumors [7]. Previously, genistein is known to inhibit the growth of lung cancer by
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downregulating essential oncoproteins, phosphorylated protein kinase, strain AK, Thymoma (pAKT),
and phosphorylated phosphoinositide-3 kinase (p-PI3K) [7].
Specifically, genistein was shown to inhibit A549 cells proliferation via miR-27a-mediated MET
signaling [8]. Genistein has also been shown to have in vitro anticancer effect in breast cancer and
prostate cancer cells [8]. Considering the fact that these genistein and miRNA-29b attack different
targets in cancer, we hypothesize that the combination of miRNA-29b and genistein will provide an
additive effect in the treatment of NSCLC. We believe that the simultaneous induction of cell death
by an anticancer drug (genistein) and suppression of antiapoptotic defense/stimulation of apoptosis
(miRNA-29b) will enhance the treatment of NSCLC. To enhance selective delivery of these payloads
to NSCLC, Genistein-miRNA-29b-loaded hybrid nanoparticles (GMLHN) are conjugated to MUC
1-aptamer for targeted delivery to NSCLC while avoiding all the well-documented side effects associated
with miRNA-nanoparticle therapeutics. MUC 1 is a cell membrane-located oncoproteins. Its level of
expression in NSCLC is abnormally high in comparison to normal cells [9,10]. Immunohistochemistry
analysis has shown that it is abnormally high in 80% of adenocarcinoma cells of the lung [9,10]. Taking
advantage of this abnormally high expression in NSCLC, we have conjugated MUC 1 aptamer to the
surface of our hybrid nanoparticles to achieve an optimized targeting of miRNA-29b and genistein to
NSCLC [11,12].
2. Materials and Methods
2.1. Materials
Lyophilized human immunoglobulin G was obtained from Equitech-Bio Inc. (Kerrville, TX,
USA). Fetal bovine serum (FBS), Poloxamer-188, as well as 4,6-diamidino-2-phenylindole (DAPI)
were purchased from Thermo Fisher Scientific, Waltham, MA, USA. GE Healthcare Bio-Sciences
Corp., Piscataway, NJ, USA supplied Aptamer against anti-MUC1 aptamer. The design tool on
the website of GE Healthcare was used to attach a C12 spacer to the 3′-end of 5′-GCA GTT GAT
CCT TTG GAT ACC CTG G-C12H25-NH2-3′. One variant of the anti-MUC1 aptamer was made
fluorescent by attaching FITC to the 5′ position. The sequence for the MUC 1-aptamer was obtained
from Wang et al. [10]. 6-FAM-labeled-siGLO used as a fluorescent-control miRNA, was also obtained
from GE Healthcare Bio-Sciences Corp. Hydrochloric acid solution was supplied by Thermo Fisher
Scientific. All other primary antibodies were purchased from Cell Signalling (Danvers, MA, USA).
Pierce Radioimmunoprecipitation assay (RIPA) lysis buffer was bought from Thermo Fisher Scientific.
miRIDIAN mimic negative control and miRIDIAN mimic miR-29b were obtained from GE Healthcare
Bio-Sciences Corp. Genistein was obtained from Shaanxi Yi, Company Limited (Shaanxi, China).
2.2. Cell Culture
A549, that was originally obtained from a 14-week male Caucasian fetus and MRC-5 cell line were
obtained from American Type Culture Collection, Rockville, MD, USA. A549 and MRC-5 cells were
maintained in F12 K medium and Eagle’s Minimum Essential Medium respectively. 10% FBS was
added to each media as supplements. Cells were incubated in a humidified air atmosphere with 5%
carbon dioxide.
2.3. Methods
2.3.1. Production of Nanoparticles
The nanoparticle preparation medium contained 1 mg/mL of human IgG in 0.01 N hydrochloric
acid. 4.38 mg of genistein and 0.73 mg of miRNA-29b or siGLO were dissolved in the medium while
gently stirred by a magnetic stirrer. While monitoring the pH of the medium, 0.01 N sodium hydroxide
was slowly added to the medium until a pH value of 7 was attained. This led to the spontaneous
formation of the nanoparticles. The nanoparticle suspension was allowed to continue to mix for 10 min,
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after which it was aliquoted into several Eppendorf tubes to be centrifuged at 2000 rpm for 5 min.
Supernatants recovered were used to determine both encapsulation efficiency (EE) and loading capacity
(LC), using HPLC for analysis. Nanoparticles were coating with 0.2% v/v carbonyl-functionalized
poloxamer-188. Conjugation of aptamer to nanoparticles was accomplished using a published
conjugation processed [10,11]. In summary, 50 µL of nanoparticle suspension (10 µg/mL in DNase,
RNase-free water) was added to 100 µL of 40 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDC) and 100 µL of 10 mM N-hydroxysulfosuccinimide (NHS) for 15 min at 20 ◦C
on a magnetic stirrer. 50 µL of 1 µg/mL MUC 1-aptamer in DNase, prepared in RNAse-free water
was mixed with the nanoparticles on a magnetic stirrer for 2 h at 20 ◦C. Aptamer-functionalized
nanoparticles were separated from unconjugated aptamer, EDC and NHS by centrifuging using 30 kDa
cutoff centrifugal ultrafilters (EMD Millipore, Billerica, MA, USA) at 4000 rpm and 10 ◦C for 5 min. To
coat the nanoparticles with poloxamer-188, aptamer-functionalized nanoparticles were then suspended
in 0.2% v/v poloxamer-188, on a magnetic stirrer for 10 min.
2.3.2. Particle Size Measurement
Dynamic light scattering (ZetaSizer Nano ZS; Malvern Instruments, Malvern, UK) was used
to determine the particle size and the ζ (zeta potential) of produced nanoparticles. In summary,
nanoparticles were suspended in water and sonicated for ~5 min in order to disperse them. A scattering
angle (θ) of 173◦ was used to measure intensity autocorrelation. Each sample was measured three
times and recorded using the Malvern Instruments software.
2.3.3. Fourier Transform-infrared Spectroscopy (FT-IR)
Samples were analyzed for FT-IR using an iS10 FT-IR spectrometer (Thermo Fisher Scientific)
installed with the attenuated total reflectance (ATR) crystal of a single-reflection-ATR with a diamond
internal reflection crystal. Multiple spectra were obtained from different samples of nanoparticles.
Background spectra were first collected before samples were mounted. Using OMNIC software, spectra
for each sample were collected at 4 cm−1 resolution
2.3.4. Scanning Electron Microscopy (SEM)
GMLHN nanoparticles suspended in double distilled deionized water were sampled on to a
double–sided carbon disc on an aluminum stub. The samples were air-dried at 25 ◦C. Palladium was
used as a coating agent before mounting the samples on a Zeiss Supra 50 V system (Carl Zeiss Meditec
AG, Jena, Germany).
2.3.5. Drug Release Study
Drug release from GMLHN was monitored using relevant buffers at pH values 5, 6.6, and 7.4.
GMLHN (3 mg) was dispersed in 0.5 mL of relevant solution and then transferred into a dialysis
membrane made of cellulose. These tubular membranes were secured at both ends. These membranes
were then placed in beakers filled with 5 mL buffered solution and stored at 37 ◦C. The cumulative
release of drug was monitored by using HPLC analysis and plotted against time
2.3.6. Fluorescence Microscopy
Using an eight-well coated glass slide purchased from Discovery Labware (Tewksbury, MA),
2 × 104 cell were incubated for 48 h. Media were then decanted from the wells and replaced with PBS
to wash three times. Opti-Mem medium containing 100 µg/mL of nanoparticles was then added to the
wells and incubated for 4 h.
After washing with PBS, 2% paraformaldehyde was used as a fixing agent, while 5% BSA was
used as a blocking agent. Lysotracker-Red and DAPI were added to the cells to visualize endosomes
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and nucleus, respectively. Cells were then mounted overnight before collecting fluorescent images
using Leica DMI 6000B microscope (Leica Microsystems, Wetzlar, Germany).
2.3.7. Cell Viability Study
Each well of a 96-well plate was seeded with 1 × 104 A549 cells. Following incubation for 24 h at
37 ◦C and 5% carbon dioxide, different concentrations of GMLHN, miRNA-29b-loaded nanoparticle,
genistein-loaded nanoparticles, control miRNA-loaded nanoparticles, control miRNA-genistein-loaded
nanoparticles, physical mixture of genistein and miRNA-29b, lipofectamine-miRNA-29b and PBS in
Opti-MEM, were added after PBS wash. The cells were then incubated for 7 h. The samples were then
replaced with F12 K medium supplemented with 10% FBS and 1% antibiotics and incubated for 3 days.
Ten µL of 12 mmol/L 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent was
then added to the wells to replace the media and incubated for 4 h at 37 ◦C. After the MTT reagent
was aspired, sterile DMSO was added and mixed thoroughly. UV absorptions of 540 nm and 650 nm
were recorded.
2.3.8. Western Blot Analysis
1 × 106 A549 cells were seeded per well and incubated for 48 h. Cells were then treated with
formulations containing genistein and miRNA-29b at a concentration of 50 nM of miRNA-29 and 1.6 M
of genistein in Opti-MEM medium for 72 h. RIPA buffer containing Pierce™ Protease Inhibitor Mini
Tablets were added for cell lysis and kept on ice for 30 min. Cells were then subjected to centrifugation
at 10,000× g for 10 min. Following the determination of protein concentration. Proteins were subjected
to electrophoresis before transferring content of the gel to nitrocellulose membrane with a pore size of
0.22 µm (Thermo Fisher Scientific). Appropriate primary antibodies overnight were added at 4 ◦C.
After washing membranes with wash buffer thrice, secondary antibodies, conjugated with horseradish
peroxidase at a dilution of 1:1000 was added to the membrane. Pierce ECL Western chemiluminescent
substrate was used to detect immune complexes.
2.3.9. Cell-Death Detection ELISA
Cell death by apoptosis was measured using cell-death detection ELISA (Hoffman-La Roche
Ltd., Basel, Switzerland). After seeding A549 at a density of 2 × 104/well, cells were treated with
various formulations containing equivalent of 50 nM of miRNA-29 and 1.6 M of genistein in Opti-MEM
medium for 72 h. Cells were lysed in incubation buffer at room temperature. The cells were then
centrifuged at 4000× g for 10 min, before collecting the supernatants. Coated plastic wells were filled
with 100 µL of homogenate and incubated at 20 ◦C for 90 min. Wells were washed thrice after decanting
the homogenate before adding the conjugate solution to the wells. For color development, ABTS
substrate was added and incubated for 30 min. BioTek Epoch Microplate Spectrophotometer (BioTek
Instruments Inc., Winooski, VT, USA) was used to collect absorption values and recorded using Gen5
1.10 software.
2.3.10. Statistical Analysis
All results were obtained at least thrice unless otherwise stated, to enable the presentation of
the results as mean ± SD. Where necessary, two statistically different data were determined using the
two-tailed Student’s t-test.
3. Results
3.1. Characterization of Nanoparticles
Figure 1A reveals that MUC 1-aptamer functionalized GMLHN nanoparticles are spherical in
nature as captured by SEM. Particle size analysis by dynamic light scattering (Table 1) confirms that
the GMLHN nanoparticles were bigger in size than the unfunctionalized GMLHN nanoparticles. The
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presence of MUC 1-aptamer on the surface of GMLHN nanoparticles led to the conversion of the
surface charge from −2.2 mV from the unfunctionalized nanoparticles to 4.2 mV.
FT-IR spectra in Figure 1B demonstrate the differences in the spectra of both MUC 1-aptamer
functionalized GMLHN and unfunctionalized GMLHN. FT-IR spectra in Figure 1B demonstrates the
conjugation of anti-MUC 1 aptamer to GMLHN. The peak at 3274 cm−1 found in the non-functionalized
GMLHN spectrum can be attributed to the amide stretching vibration of both NH2 and OH in the
nanoparticles [13]. Interestingly, a more prominent and sharper peak was observed at the same
wavelength probably due to the presence of additional NH2 and OH stretching vibration from the
amide bond due to the conjugation of NH2 in the anti-MUC1 aptamer to the GMLHN. The peak at
approximately 1541 cm−1, seen for both GMLHN and anti-MUC 1 aptamer functionalized GMLHN
could be attributable amide II carbonyl stretching from human IgG [13]. Further, at approximately
1720 cm−1, a peak is present in the spectra for MUC 1-aptamer functionalized GMLHN but absent in
the non-functionalized GMLHN. This peak is attributed to conjugated amide stretching due to the
conjugation of NH2 from the aptamer to the carboxyl groups present in the GMLHN. Further, the NH
(out of plane) bond at approximately 1112.74 cm−1 present in the aptamer functionalized GMLHN
spectrum is attributable to the presence of the aptamer on the nanoparticles.
Release of genistein and miRNA-29b from MUC 1-aptamer functionalized GMLHN was monitored
for a period of 90 h (approximately 4 days) at pH 5, 6.6 and 7.4 in Figure 1C,D. Optimal release was
observed at pH value of 5, where 100% release of miRNA-29b and genistein was achieved before 80 h.
However, less amount of both payloads were released at less acidic pH values of 6.6 and 7.4.
The EE of miRNA-29b and genistein in GMLHN were calculated to be 98.8 ± 0.4% and 99.2 ± 0.6%
respectively while LC were calculated to be 8.6 ± 0.1% and 51.8 ± 0.5% respectively.
Figure 1. Cont.
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nucleus. The merged panel for both A549 especially, shows some co-localization of nanoparticles and 
endosome suggesting some nanoparticles were still in the endosome after 4 h of incubation. 
Figure 1. Nanoparticle haracterization. (A) SEM microscopy of GMLHN showing the nanoparticles
are spherical. (B) FT-IR spectra of GMLHN and MUC 1-aptamer confirming the covalent conjugation
of aptamer to the nanoparticles. (C) R lease profile of miRNA-29b from MUC 1-apta er functionalized
GMLHN at different pH values (D) Release profile of g nist in from MUC 1-aptamer functionalized
GMLHN at d fferent pH values.
Table 1. Particle size analysis by dynamic light scattering and net charge on nanoparticles.
Samples Particle Size ± SD (nm) PDI * ± SD Zeta Potential ± SD(ζ, mV)
GMLHN 240.8 ± 41.2 0.242 ± 0.021 −2.2 ± 1.8
MUC 1-aptamer
functionalized GMLHN 598 ± 34.1 0.414 ± 0.241 4.2 ± 1.2
* PDI: Polydispersity Index.
3.2. Cellular Uptake of MUC 1-Aptamer Functionalized GMLHN
Fluorescence microscopy in Figure 2 shows limited delivery of MUC 1-aptamer functionalized
nanoparticles to normal lung fibroblast MRC-5 cells. Conversely, adenocarcinoma A549 cells show a
greater accumulation of MUC 1-aptamer functionalized nanoparticles intracellularly. Lysotracker-red
was used to label late endosome/lysosomes while DAPI (blue) was used for labelling of the nucleus.
The merged panel for both A549 especially, shows some co-localization of nanoparticles and endosome
suggesting some nanoparticles were still in the endosome after 4 h of incubation.
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3.3. Western Blot Analysis
The effect of the combination of genistein and miRNA-29b loaded in the MUC 1-aptamer
functionalized GMLHN nanoparticles on the expression of relevant oncoproteins was assessed using
western blot analysis. Figure 3 demonstrates an efficient downregulation of pAKT by GMLHN in
comparison to miRNA-29b-loaded nanoparticles as well as genistein powder. Similar trend was
observed with p-PI3K, suggesting that GMLHN nanoparticles were able to stably inhibit the expression
of these two oncoproteins in A549. In contrast, AKT and PI3K were not downregulated in A549 cells
by any of the formulations, showing the specificity of genistein, whether loaded into a nanoparticle
or used as a powder. Oncoproteins that are well known to be downregulated by miRNA-29b
MCL-1 and DNMT3B were effectively downregulated by GMLHN nanoparticles even more efficiently
than lipofectamine-200.
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3.4. Antiproliferation Effect of GMLHN in A549 Cells
The antiproliferative effect of GMLHN nanoparticles on A549 cells was assessed by MTT
assay and compared to various controls. Figure 4A demonstrates that GMLHN produced a far
superior antiproliferative effect against A549 cells when compared to individual miRNA-29b and
genistein-loaded nanoparticles. Similarly, in Figure 4B, GMLHN produced a superior apoptotic effect
in A549 cells, as measured by cell-death detection ELISA, than all other formulations tested, confirming
that nanoparticles loaded with a combination of miRNA-29b and genistein are more effective in
inhibiting the growth of lung cancer cells than nanoparticles loaded with individual miRNA-29
and genistein.
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Figure 4. Antiproliferative effect and apoptosis. ( ) T assay showing the antiproliferative effect of
GMLHN, (B) Initiation of apoptosis in A549 cells as measured by cell death detection ELISA. p≤ 0.001,n= 3.
miRNA-29b-nano = miRNA-29b-loaded nanoparticles; genistein-nano = genistein-loaded nanoparticles;
ctrlmiRNA-nano = controlmiRNA-loaded nanoparticles; genistein+miRNA-29b = physical mixture of
genistein and miRNA-29b.
4. Discussion
This study aimed to co-encapsulate miRNA-29b with genistein in our nanoparticles (GMLHN) to
produce a combination therapy that will effectively treat NSCLC. The overarching hypothesis of this
proposal is that MUC1-aptamer functionalized hybrid nanoparticle will efficiently deliver a combination
of miRNA-29b and genistein to NSCLC. Successful delivery of genistein- iRNA-29b-loaded hybrid
nanoparticles (GMLHN) will significantly inhibit NSCLC tumor by d wnregulating ssential
oncoproteins, phosphorylat d AKT (pAKT), phosphorylated phosphoi ositide-3 kinase (p-PI3K),
myeloid cell leukemia sequence 1 (MCL 1) and DNA methyltransferase 3B (DNMT3B). miRNA-29b
is known to regulate cell proliferation, differentiation and apoptosis, hence they have a significant
role to play in cancer [1,14–18]. Expression of miRNA-29b is known to be reduced in lung cancer and
other types of cancer [16]. Conversely, DNMTB expression was significantly reduced as a result of forced
expression of miRNA-29b by direct interaction at both protein and mRNA levels [1]. Further, MCL1, a
potent oncoproteins which belongs to the BCL-2 family is known to be inhibited miR-29b in cancer cells [1].
Genistein is a natural isoflavonoid that is abundantly found in soy products. It increases the
anti-neoplastic effect of some chemotherapeutic agents, hence is a potential drug in multiple tumor
types [7]. Previously, genistein has been reported to inhibit the growth of lung cancer by downregulating
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essential oncoproteins, phosphorylated AKT (pAKT), and phosphorylated phosphoinositide-3 kinase
(p-PI3K) (7). pAKT is an important factor in the growth and survival of tumour cells often enabling
the chemoresistance of cancer cells. Chemoresistance of cancer cells has been shown severally to be
significantly regulated by the PI3K/AKT pathway [18,19]. AKT phosphorylation has been shown to
play a role as a prognostic tool in breast, prostate and non-small cell lung cancer [20,21].
Considering the fact that miRNA-29b and genistein attack different targets in cancer, we
hypothesize that the combination of miRNA-29b and genistein will provide an additive effect in the
treatment of NSCLC. However, to ensure precise and targeted delivery, these molecules were loaded
into hybrid nanoparticles fabricated with a combination of human IgG and poloxamer-188. These
nanoparticles were than functionalized with MUC 1-aptamer to enable a selective delivery of these
payloads to NSCLC. These hybrid nanoparticles functionalized with MUC 1-aptamer, loaded with
miRNA-29b as a single therapy have been previously characterized extensively to ensure consistent
production [22,23]. We were also able to show that MUC 1 protein is expressed in NSCLC but not in
normal healthy cells [21].
In this present study, we loaded both miRNA-29b and genistein in these nanoparticles to elicit an
additive effect in the treatment of NSCLC.
As shown in Figure 1A, the spontaneous production of the nanoparticles lead to the production of
spherical particles. FT-IR spectroscopy was used to confirm the covalent conjugation of anti-MUC 1
aptamer to the nanoparticles. Detailed explanation of crucial peaks in the FT-IR spectra was given
in the result section. In Figure 1C,D, miRNA-29b and genistein were efficiently released at pH 5
unlike at pH 7.4 and 6.6. The significance of this is that pH 5 represents the pH value for late
endosome/lysosome, while pH values 7.4 and 6.6 represent the approximate pH values for blood and
tumor microenvironment respectively [24,25]. Ideally, we do not expect the payloads to be released in
the blood or in the tumor microenvironment but in the cytoplasm of cancer cells. The acidic pH of the
endosome facilitates the gradual dissolution of the IgG in the endosome which allows a steady release
of the payload in the endosome. This is because the pH of the endosome is lower than the isoelectric
point of human IgG which is 7. Hence, enabling the gradual dissolution of the nanoparticles at pH 5.
miRNA-29b and genistein had limited released at pH values 6.6 possibly due to the fact that IgG is not
soluble at pH values very close the its isoelectric point. Same argument could be made for the low
release at pH 7.4. Proteins typically do not dissolve at pH values close to their isoelectric point [12].
This concept is backed by the efficient internalization of siGLO-FAM in Figure 2, which demonstrates
the successful delivery of the loaded siGLO-FAM in the cytoplasm of A549 cells, enabled by the
presence of MUC 1 on the surface of these cells. In contrast, siGLO-FAM was not efficiently delivered
to the cytoplasm of MRC-5 due to the absence of MUC 1 on the surface of MRC-5 cells. The increase in
the diameter of the MUC 1-aptamer functionalized GMLHN nanoparticles over the nonfunctionalized
counterpart is mainly due to the presence of aptamer on the surface of the nanoparticles.
The negative charge on the nonfunctionalized GMLHN nanoparticles could be attributable to the
presence of residual miRNA on the surface of the nanoparticles. In contrast, the positive charge on the
MUC 1-aptamer functionalized nanoparticles could be attributed to the amino group (NH2) in the
aptamer. The presence of hycrochloric acid lead to the loss of the lone pair of electrons on the amino
group resulted in the positive charges.
The main objective behind our codelivery of miRNA-29b and genistein is to effect the
simultaneous induction of cell death by an anticancer drug (genistein) and suppression of antiapoptotic
defense/stimulation of apoptosis (miRNA-29b) to enhance the treatment of NSCLC. miRNA-29b is
known to limit cancer growth by regulating the proliferation of cells and enhancing apoptosis [21].
MiRNA-29b is known to downregulate DNMT3B and MCL1 amongst other oncogenes [6,26]. Genistein,
on the other hand, inhibits lung cancer cell growth by downregulating essential oncoproteins, pAKT)
and p-PI3K (7). Figure 3 demonstrates that GMLHN nanoparticles were able to downregulate both
pAKT and p-PI3K in A549 cells, better in comparison to miRNA-29b-loaded nanoparticles and
unencapsulated genistein. Although, both oncoproteins were downregulated, the total levels of
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PI3K or AKT were not altered, which are needed for normal cell function. Similarly, oncoproteins
DNMT3B and MCL1, were efficiently downregulated by anti-MUC 1 aptamer functionalized GMLHN
nanoparticles than miRNA-29b-loaded nanoparticles, lipofectamine-miRNA-29b, negative control
and miRNA-loaded nanoparticles. These results suggest that the MUC 1-functioanlized GMLHN
nanoparticles were very effective in downregulating the targeted oncoproteins. The effect of the
downregulation of these oncoproteins on the anti-cancer effect of GMLHN is demonstrated in
Figure 4A, which shows that GMLHN demonstrated a more potent growth inhibition in A549 cells
when compared to other formulations tested. Further, reduced expression of these oncoproteins led to
increased apoptosis in A549 cells, more effectively that individually loaded miRNA-29b and genistein
in the nanoparticles. The amount of miRNA-29b and genistein used for nanoparticle production was
based on the ratio we plan to use for in vivo study in mice. Our previous study demonstrated that our
nanoparticles containing up to 20 mg/mL of miRNA-29b are well tolerated and previous report had
shown that miRNA-29b is most effective in NSCLC tumor-bearing mice at a dose of 1.5 mg/kg [16].
Further, genistein loaded in our nanoparticle was found to be tolerated by mice up to a dose of
10 mg/kg, hence we decided to use a of dose 9 mg/kg in future mice studies. The ratio of the doses
for both miRNA-29b and genistein resulted in 1:6 (miRNA-29b:genistein), hence, nanoparticles were
fabricated with 0.73 mg and 4.38 mg of miRNA-29b and genistein (1:6) respectively. The LC of both
miRNA-29b and genistein in GMLHN reflected a 1:6 ratio (8.6:51.1%). These cells were treated with
GMLHN containing an equivalent of 50 nM of miRNA-29 and 1.6 M of genistein. These concentrations
are equivalent to 1:6 ratio by weight of miRNA-29b and genistein. The same concentrations of 50 nM
and 1.6 M of miRNA-29b and genistein was used for all the relevant formulations.
5. Conclusions
Results generated were able to demonstrate that genistein-miRNA-29b-loaded hybrid nanoparticles
(GMLHN) could be a potential treatment modality for NSCLC because of the ability of the payloads to
attack multiple targets, hence resulting in an increased anti-cancer effect. Further, increased apoptosis
was demonstrated by GMLHN over individual miRNA-29b and genistein-loaded nanoparticles.
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